Stool test may detect stomach cancer risk before symptoms appear

NCT ID NCT06943781

Recruiting now Diagnosis Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a new, non-invasive stool test that looks for specific gene changes in H. pylori bacteria linked to stomach cancer. Researchers will compare the test's accuracy with a standard risk questionnaire in 15,000 adults aged 40 and older. The goal is to see if this simple test can help catch gastric cancer earlier, when it's more treatable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fecal Helicobacter pylori gastric cancer susceptibility gene test
What this could lead to: If successful, this could provide a simple, non-invasive stool test to identify people at high risk for gastric cancer, enabling earlier diagnosis and treatment.
What could go wrong: This is an early-stage study focused on diagnostic accuracy, not treatment. The test may not prove reliable enough for widespread use, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC ADENOCARCINOMA HELICOBACTER PYLORI

Contacts and locations

Locations

People's Hospital of Tongling City
RECRUITING

Tongling, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.